Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
87%
Cardiovascular Disease
71%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
50%
Acute Heart Infarction
50%
Inflammation
44%
Protein Kinase
42%
Atrial Fibrillation
41%
Cilostazol
37%
Immunogenicity
37%
Protein Tyrosine Kinase Inhibitor
37%
Thrombomodulin
37%
Congestive Heart Failure
35%
Biological Marker
34%
Heart Injury
33%
Heart Ventricle Extrasystole
31%
Diseases
30%
Cardiotoxicity
30%
Coronary Artery Disease
30%
Observational Study
29%
Atherosclerosis
29%
Rho Kinase
28%
Doxorubicin
28%
Low Density Lipoprotein Cholesterol
28%
Clopidogrel
26%
Prasugrel
25%
Aortic Stenosis
25%
SARS Coronavirus
25%
Mitogen Activated Protein Kinase
25%
Cerebrovascular Accident
23%
Diabetes Mellitus
22%
Atorvastatin
22%
Clinical Trial
22%
Heart Disease
22%
Familial Hypercholesterolemia
22%
Heart Ventricle Hypertrophy
21%
Heart Ventricle Remodeling
20%
Combination Therapy
20%
Heart Infarction
20%
Proprotein Convertase 9
20%
Placebo
18%
Troponin T
17%
Randomized Controlled Trial
17%
Breast Cancer
16%
Ischemia
16%
Statin (Protein)
16%
Potassium Ion
15%
Cardiovascular Mortality
15%
Peripheral Occlusive Artery Disease
15%
Malignant Neoplasm
15%
Fibrosis
15%
Medicine and Dentistry
Cardiology
100%
Cardiovascular Disease
72%
Cardiovascular System
52%
Congestive Heart Failure
38%
Geriatrics
37%
Sarcopenia
35%
Hospital Mortality
33%
Atrial Fibrillation
31%
Patient with Type 2 Diabetes
31%
Cardiac Muscle Cell
29%
Nutritional Status
27%
Kidney Function
27%
Medicine
25%
Odds Ratio
25%
Infective Endocarditis
25%
Genetic Risk
25%
Induced Pluripotent Stem Cell
25%
In-Stent Restenosis
25%
Acute Heart Infarction
25%
Drug-Eluting Stent
25%
Acute Coronary Syndrome
25%
Diabetes
25%
Apoplexy
23%
Hazard Ratio
22%
Percutaneous Coronary Intervention
22%
Combination Therapy
19%
Maturity Onset Diabetes of the Young
19%
Thrombosis
18%
Chronic Total Occlusion
18%
Left Atrial Enlargement
18%
Pulmonary Embolism
18%
Diseases
17%
Antidiabetic Agent
17%
Observational Study
16%
Meta-Analysis
16%
Radiation Therapy
15%
Heart Left Ventricle Ejection Fraction
15%
Health Care Cost
15%
Protein Kinase
15%
Cancer Therapy
15%
Myocardium
14%
Rho Kinase
14%
Premature Ventricular Contraction
14%
Physical Activity
13%
Drug Therapy
13%
Anthropometry
13%
Immunogenicity
13%
Retrospective Study
13%
Randomized Controlled Trial
13%
Cell Signaling Pathway
13%
Keyphrases
Percutaneous Coronary Intervention
37%
Taiwan
27%
Taiwan Society of Cardiology
25%
Breast Cancer Patients
25%
Acute Coronary Syndrome
25%
Sarcopenia
23%
Homozygous Familial Hypercholesterolemia (HoFH)
20%
Left Atrial Enlargement
18%
Randomized Controlled Trial
18%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
16%
Low-density Lipoprotein Cholesterol (LDL-C)
15%
Acute Myocardial Infarction
15%
Cardiomyocytes
14%
Cardiac Function
14%
Dapagliflozin
12%
Extension Catheter
12%
Pentagalloyl Glucose
12%
Get With The Guidelines
12%
Atrial Fibrillation
12%
Complex Coronary Intervention
12%
Manual Compression
12%
Point-of-care Detection
12%
Adenosine Monophosphate-activated Protein Kinase Pathway
12%
Clinical Outcomes
12%
Single Coronary Artery Anomaly
12%
Sick Sinus Syndrome
12%
CYP2J2
12%
Right Ventricular Pacing
12%
Ambulatory Blood Pressure
12%
Occupational Health Care
12%
Anthropometric Predictors
12%
Hippocampal Neurons
12%
Cyclin-dependent Kinase 4/6 Inhibitors
12%
Cyclin-dependent Kinase 6 (CDK6)
12%
Novel Therapies
12%
Cost-effectiveness
12%
Verteporfin
12%
Benzoporphyrin
12%
Cardiovascular Intervention
12%
Genetic Risk Score
12%
Antihypertensive Medication Adherence
12%
Thrombosis
12%
LIM-only Protein
12%
Direct Action
12%
Vascular Senescence
12%
Platelet Volume
12%
M-type
12%
Blood Pressure Target
12%
Femoral Vein Compression
12%
Hypertension Management
12%
